Omeros (LTS:0KBU) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Omeros ROE % Adjusted to Book Value?

Omeros's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Omeros's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Omeros's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Omeros ROE % Adjusted to Book Value Historical Data

The historical data trend for Omeros's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros ROE % Adjusted to Book Value Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

Negative Equity

53.15

Omeros Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Omeros's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Omeros's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Omeros's ROE % Adjusted to Book Value falls into.

Omeros ROE % Adjusted to Book Value Calculation

Omeros's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-388.17%	/	N/A
	=	N/A

Omeros's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Omeros ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Omeros's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (LTS:0KBU) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros Headlines

No Headlines